Cortistatin-29 (reduced)

Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC50 values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects[1][2][3][4].

Product Specifications

UNSPSC

12352209

Target

Somatostatin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cortistatin-29-reduced.html

Purity

98.12

Solubility

H2O : 100 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC([C@@H](N1)CCC1=O)=O)CCC(O)=O)N[C@H](C(N2[C@H](C(N3[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N4[C@H](C(N5[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N6[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CCCCN)=O)CS)=O)CO)=O)CO)=O)CC7=CC=CC=C7)=O)[C@@H](C)O)=O)CCCCN)=O)CC8=CNC9=CC=CC=C89)=O)CC%10=CC=CC=C%10)=O)CC%11=CC=CC=C%11)=O)CC(N)=O)=O)CCCCN)=O)CS)=O)CCC6)=O)CCCCN)=O)CCCCN)=O)CC(O)=O)=O)CCCNC(N)=N)=O)CC%12=CNC=N%12)=O)CCC5)=O)CCC4)=O)CCC(N)=O)=O)CCC(N)=O)=O)CC(C)C)=O)CCC3)=O)CCC2)=O)CCCNC(N)=N

Molecular Formula

C161H242N46O41S2

Molecular Weight

3539.77

References & Citations

[1]Falo CP, et al. The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury. Pharmaceutics. 2021 Jun 24;13 (7) :947.|[2]Baranowska B, et al. Direct effect of cortistatin on GH release from cultured pituitary cells in the rat. Neuro Endocrinol Lett. 2006 Feb-Apr;27 (1-2) :153-6.|[3]Spier AD, et al. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Brain Res Rev. 2000 Sep;33 (2-3) :228-41.|[4]Benitez R, et al. Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic- and cholestatic-induced liver injury. Br J Pharmacol. 2022 May;179 (10) :2275-2296.